Direct oral anticoagulants have been an increasingly used class of drugs in the setting of
nonvalvular atrial fibrillation, defying vitamin K antagonists' monopoly when it comes to …

Introduction For a long time, vitamin K antagonists (VKA) were the only oral anticoagulation
therapy available to reduce adverse events in atrial fibrillation (AF) patients. Direct-acting …

Background: The aim of the study was to evaluate the efficacy and safety of direct oral
anticoagulants (DOACs) in a subgroup of patients with atrial fibrillation (AF), CHADS2 …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Atrial fibrillation (AF) is a significant risk factor for stroke and peripheral thromboembolic
events (TEs). Preventing blood clots in the heart to reduce stroke and TE risk is a key goal of …

Aims The aim of this study was to compare the clinical effectiveness and safety of direct oral
anticoagulants (DOACs) in patients with atrial fibrillation (AF) in routine clinical practice …

Atrial Fibrillation (AF) is accompanied by an increased risk for thromboembolic events in
most affected patients. Current guidelines therefore recommend antithrombotic therapy with …

Background There are no head-to-head randomized controlled trials comparing different
direct oral anticoagulants (DOACs). Thus, we systematically reviewed and meta-analyzed …

Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to
vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or …

Anticoagulation options have expanded over the last few decades, providing a greater
variety of medications for thromboembolic disease prevention and management. Direct oral …